<DOC>
	<DOCNO>NCT01982045</DOCNO>
	<brief_summary>The purpose study demonstrate non-inferiority AttraX® Putty bone graft substitute autograft instrument posterolateral fusion thoracolumbar spine , term efficacy safety .</brief_summary>
	<brief_title>RCT AttraX® Putty vs. Autograft Instrumented Posterolateral Spinal Fusion</brief_title>
	<detailed_description>Spinal fusion , surgical procedure frequently use many spinal condition require stabilization vertebral column , currently perform use large amount autologous bone graft autograft . A substitute patient bone would eliminate graft harvest morbidity currently one main disadvantage . Recently , promise synthetic graft substitute develop show favorable result pre-clinical study . This product AttraX® Putty ( CE-557130 ) , bioresorbable tricalcium phosphate ( TCP ) , mixed fast resorb polymer carrier improve surgical handling . The aim current study clinically investigate AttraX® Putty alternative autologous bone graft adult patient qualify instrumented posterolateral fusion thoracolumbar spine ( T10-S1 ) . The study design patient observer blind , control , randomize , multi-center clinical trial intra-patient comparison . This mean patient own control . According randomization scheme , one side spine graft AttraX® Putty side receive bone harvest iliac crest , currently gold standard . The primary outcome study posterior spinal fusion rate one year ( base CT-scans ) , potential serious adverse event related AttraX® Putty . Secondary outcomes resorption characteristic first year , volume bridge bone mass one year , evaluation iliac crest pain , correlation posterior fusion rate presence interbody fusion one year posterior spinal fusion rate two year .</detailed_description>
	<criteria>To treat instrumented posterolateral thoracolumbar spinal fusion , without additional posteriorly insert interbody device ( PLIF , TLIF ) , ( 1 ) deformity , ( 2 ) structural instability and/or ( 3 ) expect instability result decompression spinal stenosis ; Nonresponsive least 6 month nonoperative treatment prior study enrollment ; Fusion indicate one level T10 S1/ilium region ; Willing able understand sign study specific Patient Informed Consent ; Skeletally mature 18 80 year age ; Any previous surgical attempt ( ) spinal fusion ( revision surgery ) ; Previous treatment compromise fusion surgery like irradiation ; Previous autologous bone grafting procedure compromise quality amount iliac crest bone grafting ; Indication spinal fusion traumatic reason , like spinal fracture traumatic instability ; Active spinal and/or systemic infection ; Spinal metastasis area intend fusion ; Systemic disease condition , would affect subject ability participate study requirement ability evaluate efficacy graft ( e.g . active malignancy , neuropathy ) ; At risk noncompliant ( e.g . ( recently treat ) substance abuse , detainee , likely immigrate ) ; Participation clinical trial evaluate investigational device , pharmaceutical biologics within 3 month enrollment study ; Female patient intend pregnant within 1.5 year enrollment study ; Body mass index ( BMI ) large 35 ( morbidly obese ) ; Being expect require additional surgery spinal region within next 6 month ; Current recent ( &lt; 1yr ) corticosteroid use equivalent prednisone ≥5mg/day , prescribe 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bone graft</keyword>
	<keyword>Ceramic</keyword>
	<keyword>Spinal fusion</keyword>
	<keyword>RCT</keyword>
	<keyword>Thoracolumbar region</keyword>
</DOC>